ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near New Haven, CT, USA:

Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma

This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma....

Enrolling
Melanoma
Metastatic Uveal Melanoma
Biological: Lifileucel (LN-144)

Phase 1

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Harrison, New York, United States and 1 other location

ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma...

Enrolling
Advanced Melanoma
Drug: Fianlimab
Drug: Cemiplimab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 9 other locations

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...

Active, not recruiting
Metastatic Melanoma
Biological: Lifileucel

Phase 2

Iovance Biotherapeutics

New Haven, Connecticut, United States and 56 other locations

and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before.The researchers think that a com...

Enrolling
Mucosal Melanoma
Drug: Nivolumab and/or Ipilimumab
Drug: axitinib

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Harrison, New York, United States and 1 other location

is to test the effects of the study drug, ensartinib, on the patient and the cancer. Ensartinib is a new, investigational type of treatment for melanoma...

Active, not recruiting
Melanoma
Drug: Ensartinib
Diagnostic Test: ALKATI by Customized Nanostring Assay

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Harrison, New York, United States and 3 other locations

with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma...

Enrolling
Melanoma
Drug: IO102/IO103
Drug: Nivolumab-Relatlimab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Hartford, Connecticut, United States and 8 other locations

study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma...

Active, not recruiting
Advanced Melanoma
Renal Cell Carcinoma
Drug: Nivolumab
Drug: Ipilimumab

Phase 1

Yale University
Yale University

New Haven, Connecticut, United States and 1 other location

This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma...

Enrolling
Melanoma
Metastatic Melanoma
Drug: Pembrolizumab
Drug: Lenvatinib

Phase 2

Yale University
Yale University

New Haven, Connecticut, United States

and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma...

Enrolling
Melanoma
Drug: mRNA-4157
Biological: Pembrolizumab

Phase 2

Moderna
Moderna

New Haven, Connecticut, United States and 20 other locations

with bevacizumab in patients with untreated brain metastases from melanoma or NSCLC to determine activity and safety of the drug combination...

Active, not recruiting
Melanoma
Brain Metastasis
Drug: Pembrolizumab plus Bevacizumab

Phase 2

Yale University
Yale University

New Haven, Connecticut, United States and 1 other location

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems